Abstract
AbstractThe epidemiologic link between exposure to gadolinium‐based contrast (GBC) agents and the development of nephrogenic systemic fibrosis (NSF) in patients with moderate to severe end‐stage renal disease (ESRD) has caused concern among physicians, particularly radiologists and nephrologists. The concerns of manufacturers of GBC agents and the U.S. Food and Drug Administration (FDA) have led to the publication of product label warnings and a Public Health Advisory. As more cases of NSF associated with GBC agent exposure have surfaced, manufacturers and physicians have become increasingly concerned about the potential for litigation. To date, litigation has been directed primarily at manufacturers of GBC agents and has focused on package warnings. Thus, physicians should stay abreast of FDA warnings, keep an open line of communication with manufacturers of GBC agents, and review package warnings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
